osilodrostat治疗库欣病的疗效与安全性(LINC 3):一项多中心III期研究,包含双盲随机撤药期
LINC 3是一项前瞻性、多中心、开放标签III期研究,含双盲随机撤药期,纳入137例库欣病患者。第34周时,osilodrostat组完全缓解比例高于安慰剂组(31例[86%] vs 10例[29%];OR 13.7 [95% CI 3.7-53.4];p<0.0001)。第24周时,72例(53%;95% CI 43.9-61.1)患者维持完全缓解且第12周后未上调剂量。常见不良事件为恶心、头痛、疲劳和肾上腺功能不全。
要点
- 第34周完全缓解率:osilodrostat组31例(86%)vs 安慰剂组10例(29%),OR 13.7(95% CI 3.7-53.4),p<0.0001。
- 第24周时72例(53%;95% CI 43.9-61.1)患者维持完全缓解且第12周后未上调剂量。
- 常见不良事件(>25%)为恶心57例(42%)、头痛46例(34%)、疲劳39例(28%)、肾上腺功能不全38例(28%)。
核心结论
- 每日两次osilodrostat可快速降低平均24小时尿游离皮质醇(UFC)并维持该降低,同时改善皮质醇增多症的临床体征,且总体耐受性良好。
- osilodrostat是一种有效的新治疗选择,已在欧洲获批用于治疗内源性库欣综合征,在美国获批用于治疗库欣病。
研究设计与样本
- LINC 3是一项前瞻性、多中心、开放标签III期研究,包含双盲随机撤药期,共四个阶段。
- 研究纳入18-75岁确诊持续性或复发性库欣病患者(定义:平均24小时UFC浓度>1.5倍正常上限[ULN],且晨间血浆促肾上腺皮质激素高于正常下限),患者既往接受过垂体手术或放疗,或新诊断但拒绝手术或不适合手术。
- 患者来自19个国家的66个医院中心和私人临床诊所。
- 2014年11月12日至2017年3月22日期间,筛查202例患者,纳入137例;中位年龄40.0岁(31.0-49.0),106例(77%)为女性。
- 第1阶段:所有参与者开始开放标签osilodrostat,每2周根据平均24小时UFC浓度和安全性调整剂量(1-30 mg每日两次;口服薄膜衣片),直至第12周。
主要发现
- 撤药阶段有72例(53%)参与者符合随机化条件,其中36例分配继续使用osilodrostat,35例分配使用安慰剂;1例患者因研究者决定未随机分配并继续开放标签osilodrostat。
- 第34周时,osilodrostat组维持完全缓解的患者多于安慰剂组:31例(86%)vs 10例(29%);OR 13.7(95% CI 3.7-53.4);p<0.0001。
- 第24周时,137例患者中72例(53%;95% CI 43.9-61.1)维持完全缓解且第12周后未上调剂量。
- 最常见不良事件(即发生于>25%参与者)为恶心57例(42%)、头痛46例(34%)、疲劳39例(28%)和肾上腺功能不全38例(28%)。
- 低皮质醇血症发生于70例(51%)患者,肾上腺激素前体相关不良事件发生于58例(42%)患者。
关键数值与推荐
- 完全缓解定义为平均24小时UFC浓度≤ULN且未上调剂量。
- 主要终点:第34周完全缓解率osilodrostat组31例(86%)vs 安慰剂组10例(29%),OR 13.7(95% CI 3.7-53.4),p<0.0001。
- 关键次要终点:第24周完全缓解且第12周后未上调剂量比例为72/137(53%;95% CI 43.9-61.1)。
- osilodrostat剂量范围为1-30 mg每日两次,每2周根据平均24小时UFC浓度和安全性调整。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cushing's disease is a rare endocrine disorder characterised by cortisol overproduction with severe complications. Therapies for cortisol reduction are often necessary. Here we report the outcomes from the pivotal phase III study of osilodrostat (a potent oral inhibitor of cytochrome P450 11B1, mitochondrial [11β-hydroxylase]; Novartis Pharma AG, Basel, Switzerland) in patients with Cushing's disease. METHODS: LINC 3 was a prospective, multicentre, open-label, phase III study with a double-blind randomised withdrawal period, that comprised four periods. Patients aged 18-75 years, with confirmed persistent or recurrent Cushing's disease (defined as mean 24-h urinary free cortisol [UFC] concentration >1·5 times the upper limit of normal [ULN] and morning plasma adrenocorticotropic hormone above the lower limit of normal) who had previously had pituitary surgery or irradiation, or were newly diagnosed and who refused surgery or were not surgical candidates, were recruited from 66 hospital sites and private clinical practices in 19 countries. In period 1, open-label osilodrostat was initiated in all participants and adjusted every 2 weeks (1-30 mg twice daily; film-coated tablets for oral administration) on the basis of mean 24-h UFC concentration and safety until week 12. In period 2, weeks 13-24, osilodrostat was continued at the therapeutic dose determined during period 1. In period 3, beginning at week 26, participants who had a mean 24-h UFC concentration of less than or equal to the ULN at week 24, without up-titration after week 12, were randomly assigned (1:1), via an interactive-response technology, stratified by osilodrostat dose at week 24 and history of pituitary irradiation, to continue osilodrostat or switch to placebo for 8 weeks. Participants and investigators were masked to treatment assignment. Ineligible participants continued open-label osilodrostat. In period 4, weeks 35-48, all participants were given open-label osilodrostat until core-study end. The primary objective was to compare the efficacy of osilodrostat versus placebo at the end of period 3. The primary endpoint was the proportion of participants who had been randomly assigned to treatment or placebo with a complete response (ie, mean 24-h UFC concentration of ≤ULN) at the end of the randomised withdrawal period (week 34), without up-titration during this period. The key secondary endpoint was the proportion of participants with a complete response at the end of the single-arm, open-label period (ie, period 2, week 24) without up-titration during weeks 13-24. Analysis was by intention-to-treat for all patients who received at least one dose of osilodrostat (full analysis set; key secondary endpoint) or randomised treatment (randomised analysis set; primary endpoint) and safety was assessed in all enrolled patients who received at least one dose of osilodrostat and had at least one post-baseline safety assessment. LINC 3 is registered with ClinicalTrials.gov, NCT02180217, and is now complete. FINDINGS: Between Nov 12, 2014, and March 22, 2017, 202 patients were screened and 137 were enrolled. The median age was 40·0 years (31·0-49·0) and 106 (77%) participants were female. 72 (53%) participants were eligible for randomisation during the withdrawal phase, of whom 36 were assigned to continue osilodrostat and 35 were assigned to placebo; one patient was not randomly assigned due to investigator decision and continued open-label osilodrostat. More patients maintained a complete response with osilodrostat versus with placebo at week 34 (31 [86%] vs ten [29%]; odds ratio 13·7 [95% CI 3·7-53·4]; p<0·0001). At week 24, 72 (53%; 95% CI 43·9-61·1) of 137 patients maintained a complete response without up-titration after week 12. Most common adverse events (ie, occurred in >25% of participants) were nausea (57 [42%]), headache (46 [34%]), fatigue (39 [28%]), and adrenal insufficiency (38 [28%]). Hypocortisolism occurred in 70 (51%) patients and adverse events related to adrenal hormone precursors occurred in 58 (42%) patients. One patient died, unrelated to study drug, after the core study phase. INTERPRETATION: Twice-daily osilodrostat rapidly reduced mean 24-h UFC and sustained this reduction alongside improvements in clinical signs of hypercortisolism; it was also generally well tolerated. Osilodrostat is an effective new treatment option that is approved in Europe for the treatment of endogenous Cushing's syndrome and in the USA for Cushing's disease. FUNDING: Novartis Pharma AG.
引用
- Pivonello R, Fleseriu M, Newell-Price J, et al. Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase. Lancet Diabetes Endocrinol. 2020. PMID: 32730798. doi:10.1016/S2213-8587(20)30240-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。